Symptom Management Database

Evidence-informed reference for common withdrawal symptoms. Onset timelines, expected duration, and non-pharmacological management strategies.

CalculatorSymptom ManagementSupport Resources

This information is compiled from published clinical literature and is intended as an educational reference. It does not constitute medical advice. Individual experiences vary significantly. Consult a healthcare provider for personalized guidance.

Sympathetic Nervous System Rebound Gastrointestinal Effects Sleep Disruption Mood Effects

Sympathetic Nervous System Rebound

Withdrawal removes tonic mu-opioid inhibition of the locus coeruleus, causing noradrenergic hyperactivity. These symptoms reflect unopposed sympathetic nervous system activation.

Anxiety / Agitation

Onset: 12–24 hours after last doseDuration: 5–10 days; peaks at days 2–4

Generalized anxiety, restlessness, inability to sit still. Driven by norepinephrine surge from locus coeruleus disinhibition. May manifest as racing thoughts, chest tightness, or a sense of impending doom.

Management Strategies (Non-Pharmacological)

1
Box breathing: inhale 4 seconds, hold 4, exhale 4, hold 4. Repeat for 5 minutes. Activates parasympathetic response via vagal tone.
2
Cold exposure: 30-second cold water on face or wrists. Triggers mammalian dive reflex, acutely lowering heart rate.
3
Progressive muscle relaxation: systematically tense and release each muscle group for 5 seconds. Start at feet, work up to face.
4
Limit caffeine to <100 mg/day during peak withdrawal — caffeine potentiates noradrenergic activity.
5
Structured daily routine: anxiety amplifies in unstructured time. Schedule blocks for meals, walks, tasks.

Elevated Heart Rate / Palpitations

Onset: 12–36 hours after last doseDuration: 3–7 days

Resting heart rate may increase 15–30 BPM above baseline. Caused by loss of mu-opioid-mediated vagal tone and noradrenergic surge. Not typically dangerous in otherwise healthy individuals, but can be distressing.

Management Strategies (Non-Pharmacological)

1
Monitor resting heart rate morning and evening with a pulse oximeter or wrist device. Track trend, not spikes.
2
Vagal maneuvers: bearing down (Valsalva), splashing cold water on face, or slow deep breathing can acutely reduce heart rate.
3
Light walking (20–30 min) paradoxically lowers resting heart rate over hours by engaging baroreceptor feedback.
4
Avoid stimulants, decongestants, and high-sodium meals during acute phase.
5
Seek medical evaluation if resting HR consistently >120 BPM, chest pain, or fainting.

Sweating / Temperature Dysregulation

Onset: 18–36 hours after last doseDuration: 4–8 days

Alternating hot flashes and chills. Profuse sweating, particularly at night. Reflects hypothalamic thermoregulatory disruption as opioid receptor tone shifts. Body temperature may fluctuate 1–2°F above/below normal.

Management Strategies (Non-Pharmacological)

1
Layer clothing for easy temperature adjustment. Moisture-wicking fabrics reduce discomfort.
2
Keep room temperature at 65–68°F (18–20°C), especially for sleep.
3
Electrolyte replacement: sweating depletes sodium, potassium, magnesium. Use oral rehydration solution or electrolyte powder.
4
Frequent lukewarm (not hot) showers. Hot showers may transiently feel good but worsen temperature instability.
5
Keep spare bedding — night sweats may require sheet changes. Waterproof mattress protector recommended.

Gastrointestinal Effects

Mu-opioid receptors in the enteric nervous system regulate GI motility and secretion. Withdrawal causes rebound hyperperistalsis and increased intestinal secretion.

Nausea / Vomiting

Onset: 12–24 hours after last doseDuration: 3–5 days; typically resolves before other symptoms

Ranges from mild queasiness to active vomiting. Mediated by chemoreceptor trigger zone sensitization and vagal afferent activation. Usually most intense in the first 48 hours.

Management Strategies (Non-Pharmacological)

1
Ginger: 250 mg ginger root extract 4x daily, or fresh ginger tea. Evidence-based antiemetic via 5-HT3 antagonism.
2
Small frequent meals — empty stomach worsens nausea. Bland foods: rice, toast, bananas, broth.
3
Peppermint tea or peppermint oil capsules (enteric-coated). Relaxes gastric smooth muscle.
4
Avoid lying flat after eating. Semi-reclined position at 30–45° reduces reflux-mediated nausea.
5
Acupressure: firm pressure on P6 point (inner wrist, 3 finger-widths below crease). RCT-supported for nausea reduction.

Diarrhea / Cramping

Onset: 24–48 hours after last doseDuration: 5–10 days

Loose/watery stools, abdominal cramping, urgency. Reflects loss of mu-opioid-mediated inhibition of intestinal motility and chloride secretion. Can lead to dehydration and electrolyte imbalance if severe.

Management Strategies (Non-Pharmacological)

1
Oral rehydration: water alone is insufficient. Use WHO-formula ORS or add 1/2 tsp salt + 6 tsp sugar to 1 liter water.
2
BRAT diet during acute phase: bananas, rice, applesauce, toast. Low residue, binding foods.
3
Psyllium husk (Metamucil): 1 tsp in water, 1–2x daily. Bulking fiber absorbs excess water in colon.
4
Avoid dairy, high-fat foods, artificial sweeteners, and caffeine — all worsen diarrhea.
5
Heating pad on abdomen for cramping — moist heat preferred. 20 minutes on, 20 minutes off.

Loss of Appetite

Onset: 12–24 hours after last doseDuration: 7–14 days

Reduced hunger signals, food aversion, early satiety. Combination of GI distress, autonomic dysregulation, and dysphoric mood. Caloric deficit can worsen fatigue and mood symptoms.

Management Strategies (Non-Pharmacological)

1
Calorie-dense liquids: smoothies, bone broth, protein shakes. Easier to consume than solid food.
2
Eat by schedule, not appetite. Set alarms for small meals every 3–4 hours.
3
Nutrient-dense snacks requiring minimal preparation: nuts, nut butter, cheese, hard-boiled eggs, avocado.
4
Avoid forcing large meals — smaller portions reduce GI burden and nausea risk.
5
B-complex vitamin supplement may support appetite recovery via metabolic cofactor replenishment.

Sleep Disruption

Opioid withdrawal profoundly disrupts sleep architecture. REM rebound produces vivid, often distressing dreams. Noradrenergic hyperactivity impairs sleep onset. Insomnia is frequently the most persistent withdrawal symptom.

Insomnia

Onset: First night after dose reductionDuration: 7–21 days; often the longest-lasting symptom

Difficulty falling asleep, frequent awakenings, early morning waking. Sleep latency may increase to 60–90+ minutes. Total sleep time often drops to 3–5 hours. Driven by noradrenergic hyperarousal and loss of opioid-mediated sedation.

Management Strategies (Non-Pharmacological)

1
Sleep restriction therapy: limit time in bed to actual sleep time (e.g., 5 hours). Gradually extend by 15 min as efficiency improves. Counterintuitive but evidence-based.
2
Fixed wake time regardless of sleep quality. Anchors circadian rhythm. No sleeping in.
3
No screens 60 min before bed. Blue light suppresses melatonin. Use blue-light glasses if unavoidable.
4
Room environment: blackout curtains, 65°F, white noise machine. Remove clocks from line of sight.
5
If unable to sleep after 20 minutes, get up. Do a low-stimulation activity (reading, gentle stretching) until drowsy, then return to bed.
6
Melatonin 0.5–1 mg (low dose, not 5–10 mg) 30 minutes before target sleep time. Higher doses are not more effective and disrupt sleep architecture.

Vivid Dreams / Nightmares

Onset: Nights 2–5 after dose reductionDuration: 7–14 days; intensity peaks around day 5

Extremely vivid, emotionally intense dreams. Often disturbing or themed around loss, conflict, or using. This is REM rebound — suppressed REM sleep during opioid use floods back during withdrawal, producing extended, hyper-real dream sequences.

Management Strategies (Non-Pharmacological)

1
Normalize the experience: REM rebound is a predictable neurological process, not a sign of psychological deterioration. It resolves.
2
Journaling dreams immediately upon waking can reduce their emotional persistence. Write, then close the journal.
3
Imagery Rehearsal Therapy (IRT): while awake, mentally rewrite a recurring nightmare with a neutral or positive ending. Practice the new version before sleep.
4
Avoid heavy meals, alcohol, and stimulants before bed — all worsen dream intensity.
5
Consistent sleep/wake schedule helps regularize REM distribution across the night.

Restless Legs / Periodic Limb Movements

Onset: 24–48 hours after last doseDuration: 5–14 days

Unpleasant crawling, tingling, or aching sensation in legs (and sometimes arms) with an irresistible urge to move. Worsens at rest, especially in the evening. Dopaminergic dysfunction and iron metabolism disruption contribute.

Management Strategies (Non-Pharmacological)

1
Evening walk (20–30 min) 2–3 hours before bed. Moderate exercise reduces RLS severity in clinical studies.
2
Hot bath or heating pad on legs before bed. Heat increases blood flow and may temporarily override sensory symptoms.
3
Leg massage or foam rolling. Focus on calves and anterior tibialis.
4
Compression socks (15–20 mmHg) worn in the evening may reduce sensation intensity.
5
Check ferritin levels if RLS persists >2 weeks. Iron supplementation (with vitamin C for absorption) helps if ferritin <75 ng/mL.

Mood Effects

Chronic mu-opioid receptor agonism downregulates endogenous opioid peptides (endorphins, enkephalins) and alters dopaminergic reward circuitry. Withdrawal unmasks this deficit, producing dysphoria and amotivation until endogenous tone recovers.

Irritability / Emotional Lability

Onset: 24–48 hours after last doseDuration: 7–14 days; may persist at lower intensity for 3–4 weeks

Disproportionate emotional reactions, short temper, tearfulness, frustration at minor events. Reflects both noradrenergic hyperactivity and depleted endogenous opioid buffering of emotional stimuli.

Management Strategies (Non-Pharmacological)

1
Communicate with household members: let them know irritability is a predictable, temporary neurological symptom. Set a "signal word" for when you need space.
2
Remove yourself from triggering situations for 5–10 minutes. This is not avoidance — it is impulse-control management during a neurologically compromised period.
3
Physical activity: even 10 minutes of brisk walking modulates norepinephrine and cortisol. Most effective strategy with fastest onset.
4
Journaling: writing about frustration externalizes it. 5 minutes, unstructured, then set it aside.
5
Maintain blood sugar stability — irritability worsens with hypoglycemia. Eat regular small meals.

Low Motivation / Anhedonia

Onset: 48–72 hours after last doseDuration: 14–30 days; slowest to resolve

Inability to feel pleasure from normally enjoyable activities. Flat affect, low drive, difficulty initiating tasks. Reflects dopaminergic downregulation in the nucleus accumbens and ventral tegmental area. This is the most common reason for relapse.

Management Strategies (Non-Pharmacological)

1
Behavioral activation: schedule one small pleasurable or accomplishing activity per day. Do it regardless of motivation. Action precedes motivation, not the reverse.
2
Exercise is the single most evidence-supported intervention for anhedonia. 30 min moderate cardio releases BDNF and upregulates dopamine receptors. Start with walking if energy is low.
3
Social connection: isolation worsens anhedonia. Even brief, low-effort social contact (text, phone call, coffee) helps.
4
Sunlight exposure: 15–30 min natural light in the morning. Regulates circadian dopamine rhythms.
5
Set micro-goals: "open laptop" not "finish project." Completion of tiny tasks rebuilds reward circuitry incrementally.
6
This symptom resolves — endogenous opioid and dopamine tone recovers over 2–6 weeks. Progress is not linear.

Depressed Mood

Onset: 48–72 hours after last doseDuration: 7–21 days for acute phase; may extend if pre-existing

Sadness, hopelessness, negative self-talk. Distinct from clinical depression — this is substance-withdrawal dysphoria. However, it can unmask or exacerbate pre-existing mood disorders. If symptoms persist >4 weeks or include suicidal ideation, professional evaluation is indicated.

Management Strategies (Non-Pharmacological)

1
Differentiate withdrawal dysphoria from clinical depression: withdrawal mood symptoms improve week over week. If worsening after week 3, seek evaluation.
2
Maintain basic self-care: shower, dress, eat, hydrate. These are not trivial during withdrawal — they are baseline neurological support.
3
Omega-3 fatty acids (EPA-dominant): 2–3 g/day. Meta-analyses support efficacy for depressed mood with effect sizes comparable to mild interventions.
4
Gratitude practice: write 3 specific things daily. Sounds simplistic but fMRI data shows measurable changes in prefrontal activation with consistent practice.
5
If suicidal thoughts occur: contact Crisis Text Line (text HOME to 741741) or call 988 Suicide & Crisis Lifeline. These are anonymous and immediate.

If symptoms are severe or worsening after 2 weeks, seek professional evaluation.

Visit the Support Resources page for anonymous helplines and provider locators.